Role of Biomarkers in Patients Undergoing Dialysis Treatment

University of Zurich45 enrolled

Overview

A precise volume status assessment is critical to improve outcome of patients on dialysis. Yet, accurate assessment of fluid status remains a challenge. Currently, this is performed by clinical evaluation and regular weight measurements before and after dialysis, which is not always accurate. Moreover, bioimpedance technology is used in some centers for quantitative assessment of total body water. This approach has been validated for the assessment of volume status in dialysis patients, but requires the acquisition of specific tools and is time consuming. So far, no biomarker has been validated to quantify volume status in dialysis patients. Application of biomarkers might contribute to a better dialysis prescription and therefore to outcome improvement in dialysis. The investigators aim to investigate the role of a novel biomarkers (sCD146) to assess volume status in dialysis patients

Study Type

OBSERVATIONAL

Enrollment

Conditions

Volemia in Dialysis Patients

Interventions

bioelectrical impedance measurement and biomarker measurementDEVICE

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age \> 18 years old * Patient on dialysis since \> 1 month * Voluntarily signed informed consent Exclusion Criteria: * Pregnant or breastfeeding women and women who plan to get pregnant during study * Incapability of following the study protocol * Acute illness * Hospitalizations in the last week before inclusion * Cardiac pacemakers or defibrillators * Limb amputation or other factors precluding a reliable bioimpedance measurement (unreliable bioimpedance measurement)

Outcomes

Primary Outcomes

Correlation of sCD146 level with overhydration assessed by bioimpedance technology

For hemodialysis patients measurements will be concluded within 3 weeks, for peritoneal dialysis patients measures will be concluded within 3 months

Time frame: 3 weeks to 3 months

Secondary Outcomes

Correlation of sCD146 level measured after dialysis and ultrafiltration rate

for hemodialysis patients measurements will be concluded within 3 weeks

Time frame: 3 weeks

Correlation of sCD146 level and clinical evaluation of volume status

For hemodialysis patients measurements will be concluded within 3 weeks, for peritoneal dialysis patients measures will be concluded within 3 months

Time frame: 3 weeks to 3 months

Correlation of sCD146 level and level of NT-proBNP

For hemodialysis patients measurements will be concluded within 3 weeks, for peritoneal dialysis patients measures will be concluded within 3 months

Time frame: 3 weeks to 3 months

Correlation of sCD146 level and mortality as assessed prospectively in 6 months follow-up

Time frame: 6 months

Correlation of sCD146 level and hospitalizations as assessed prospectively in 6 months follow-up

Time frame: 6 months

Correlation of sCD146 level and cardiovascular complications as assessed prospectively in 6 months follow-up

Time frame: 6 months

Correlation of sCD146 level and shunt complications as assessed prospectively in 6 months follow-up

Time frame: 6 months

Role of Biomarkers in Patients Undergoing Dialysis Treatment

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes